<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621764</url>
  </required_header>
  <id_info>
    <org_study_id>JEC01</org_study_id>
    <nct_id>NCT00621764</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children</brief_title>
  <official_title>A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety:

      To describe the safety profiles following vaccination.

      Immunogenicity:

      To describe the immune response after a single dose of vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, cross-over, open, active controlled, multi-center trial in toddlers and
      children in Thailand. Stepwise enrollment of children in 2 age cohorts. Subjects will be
      followed for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection</measure>
    <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
    <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as Second Injection</measure>
    <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
    <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to JE-CV Vaccine Antigens Following Administration of JE-CV Vaccination</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 after final vaccination</time_frame>
    <description>JE virus neutralizing antibody measurement was assessed by plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt; 10 (1/dil) and post-vaccination titer ≥ 10 (1/dil), or participants with pre-vaccination titer ≥ 10 (1/dil) and 4-fold increase from pre- to post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Geometric Mean Titers Against JE Antibodies Before and After JE-CV Vaccination</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 28 after final vaccination</time_frame>
    <description>JE virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Summary of Persistence of Seroprotection to JE-CV Antigens Up To Five Years Following Vaccination</measure>
    <time_frame>Day 0 (pre-vaccination) up to 5 years after final vaccination</time_frame>
    <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Summary of Geometric Mean Titer Against JE Antibodies Up To Five Years Following Vaccination With JE-CV Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) up to 5 years after final vaccination</time_frame>
    <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>JE-CV/Hepatitis A (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A/JE-CV (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-CV/Hepatitis A (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A/JE-CV (Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)</intervention_name>
    <description>≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)</description>
    <arm_group_label>JE-CV/Hepatitis A (Group 1)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)</intervention_name>
    <description>0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)</description>
    <arm_group_label>Hepatitis A/JE-CV (Group 2)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)</intervention_name>
    <description>≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)</description>
    <arm_group_label>JE-CV/Hepatitis A (Group 3)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)</intervention_name>
    <description>0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)</description>
    <arm_group_label>Hepatitis A/JE-CV (Group 4)</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of consent form signed by at least one parent or another legally acceptable
             representative, and by at least one independent witness.

          -  Completion of vaccinations according to the national immunization schedule

          -  Subject and parent/legally acceptable representative able to attend all scheduled
             visits and comply with all trial procedures.

          -  Previous receipt of two doses of a mouse-brain-derived JE vaccine at 12 to 15 months
             of age according to the national immunization schedule and aged 2 to 5 years on the
             day of inclusion.

          -  Aged 12 to 24 months on the day of inclusion and have not received any JE vaccine.

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination.

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy.

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the
             same substances.

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator.

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of the immune response.

          -  Receipt of hepatitis A vaccine.

          -  History of flavivirus infection (confirmed either clinically, serologically or
             microbiologically).

          -  Administration of any anti-viral within 2 months preceding the screening visit.

          -  History of central nervous system disorder or disease.

          -  Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.

          -  Planned participation in another clinical trial during the present trial period.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination.

          -  Personal human immunodeficiency virus, hepatitis B or hepatitis C seropositivity in
             the blood sample taken at screening.

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating IM vaccination.

          -  Previous vaccination against flavivirus disease at any time before the trial other
             than a mouse-brain-derived JE vaccine given in a two-dose regimen at 12 to 15 months
             of age in accordance with the national immunization schedule.

          -  Febrile illness or any acute illness/infection on the day of vaccination, according to
             investigator judgment

          -  History of seizures.

          -  Previous vaccination against flavivirus disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010 Dec;29(12):1111-7. doi: 10.1097/INF.0b013e3181f68e9c.</citation>
    <PMID>20856164</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>September 9, 2014</results_first_submitted>
  <results_first_submitted_qc>September 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese encephalitis (JE)</keyword>
  <keyword>Hepatitis A</keyword>
  <keyword>Inactivated Mouse-Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 02 March 2008 to 06 January 2009 at 3 clinic centers in Thailand.</recruitment_details>
      <pre_assignment_details>A total of 300 participants who met all of the inclusion and none of the exclusion criteria were randomized and vaccinated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JE-CV/Hepatitis A (Group 1)</title>
          <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="P2">
          <title>Hepatitis A/JE-CV (Group 2)</title>
          <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
        </group>
        <group group_id="P3">
          <title>JE-CV/Hepatitis A (Group 3)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="P4">
          <title>Hepatitis A/JE-CV (Group 4)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JE CV/Hepatitis A (Group 1)</title>
          <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="B2">
          <title>Hepatitis A/JE CV (Group 2)</title>
          <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE CV as second vaccination 28 days apart</description>
        </group>
        <group group_id="B3">
          <title>JE CV/Hepatitis A (Group 3)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of JE CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="B4">
          <title>Hepatitis A/JE CV (Group 4)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE CV as second vaccination 28 days apart</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="101"/>
            <count group_id="B4" value="99"/>
            <count group_id="B5" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="0.5"/>
                    <measurement group_id="B2" value="2.5" spread="0.6"/>
                    <measurement group_id="B3" value="1.4" spread="0.2"/>
                    <measurement group_id="B4" value="1.3" spread="0.2"/>
                    <measurement group_id="B5" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection</title>
        <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
        <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
        <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection</title>
          <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
          <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Tenderness (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="43" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="19" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Tenderness (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="23" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="14" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="18" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N=50,50,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (N=50,50,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying abnormal (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="22" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="13" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="28" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="32" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite lost (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N=0,0,101,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as Second Injection</title>
        <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
        <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
        <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine. A participant in Group 1 was given JE-CV vaccine as the second vaccination in error; and counted for Group 2 for the safety outcome for the second injection.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as Second Injection</title>
          <description>12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, &gt;39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, &gt;3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.
2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, &gt;39˚C; Headache, Malaise, and Myalgia, Prevents activities.</description>
          <population>Solicited injection site reactions and systemic reactions were assessed in the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine. A participant in Group 1 was given JE-CV vaccine as the second vaccination in error; and counted for Group 2 for the safety outcome for the second injection.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Tenderness (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Tenderness (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N=48,51,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (N=48,51,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O4" value="NA">This safety event was not solicited for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying abnormal (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite lost (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N=0,0,100,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O2" value="NA">This safety event was not solicited for this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to JE-CV Vaccine Antigens Following Administration of JE-CV Vaccination</title>
        <description>JE virus neutralizing antibody measurement was assessed by plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt; 10 (1/dil) and post-vaccination titer ≥ 10 (1/dil), or participants with pre-vaccination titer ≥ 10 (1/dil) and 4-fold increase from pre- to post-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 after final vaccination</time_frame>
        <population>Seroconversion to the JE-CV vaccine antigens was assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to JE-CV Vaccine Antigens Following Administration of JE-CV Vaccination</title>
          <description>JE virus neutralizing antibody measurement was assessed by plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt; 10 (1/dil) and post-vaccination titer ≥ 10 (1/dil), or participants with pre-vaccination titer ≥ 10 (1/dil) and 4-fold increase from pre- to post-vaccination.</description>
          <population>Seroconversion to the JE-CV vaccine antigens was assessed in the Per-Protocol Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homologous virus (N=49,48,83,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8"/>
                    <measurement group_id="O2" value="95.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="93.2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (N=49,48,81,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7"/>
                    <measurement group_id="O2" value="93.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="98.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="95.6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (N=49,48,81,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7"/>
                    <measurement group_id="O2" value="93.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96.3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="95.6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (N=49,48,81,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="91.7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="94.6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (N=49,48,81,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8"/>
                    <measurement group_id="O2" value="91.7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="74.1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="65.6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Geometric Mean Titers Against JE Antibodies Before and After JE-CV Vaccination</title>
        <description>JE virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 28 after final vaccination</time_frame>
        <population>Geometric mean titers against the JE-CV vaccine antigens were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titers Against JE Antibodies Before and After JE-CV Vaccination</title>
          <description>JE virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
          <population>Geometric mean titers against the JE-CV vaccine antigens were assessed in the Per-Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homologous virus (pre-vaccination; N=49,48,86,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="33.9" upper_limit="72.1"/>
                    <measurement group_id="O2" value="40.6" lower_limit="26.4" upper_limit="62.4"/>
                    <measurement group_id="O3" value="5.78" lower_limit="5.25" upper_limit="6.37"/>
                    <measurement group_id="O4" value="5.08" lower_limit="4.92" upper_limit="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-vaccination; N=49,48,84,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1957" lower_limit="1227" upper_limit="3120"/>
                    <measurement group_id="O2" value="3568" lower_limit="2361" upper_limit="5394"/>
                    <measurement group_id="O3" value="500" lower_limit="353" upper_limit="708"/>
                    <measurement group_id="O4" value="167" lower_limit="120" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (pre-vaccination; N=49,48,83,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="36.0" upper_limit="84.6"/>
                    <measurement group_id="O2" value="55.3" lower_limit="35.3" upper_limit="86.7"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (post-vaccination; N=49,48,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016" lower_limit="703" upper_limit="1467"/>
                    <measurement group_id="O2" value="1988" lower_limit="1427" upper_limit="2770"/>
                    <measurement group_id="O3" value="170" lower_limit="130" upper_limit="223"/>
                    <measurement group_id="O4" value="155" lower_limit="117" upper_limit="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (pre-vaccination; N=49,48,83,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="31.9" upper_limit="67.9"/>
                    <measurement group_id="O2" value="34.2" lower_limit="22.7" upper_limit="51.4"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (post-vaccination; N=49,48,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="921" lower_limit="625" upper_limit="1356"/>
                    <measurement group_id="O2" value="1566" lower_limit="1090" upper_limit="2250"/>
                    <measurement group_id="O3" value="157" lower_limit="119" upper_limit="206"/>
                    <measurement group_id="O4" value="121" lower_limit="93.7" upper_limit="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (pre-vaccination; N=49,48,83,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="27.0" upper_limit="57.0"/>
                    <measurement group_id="O2" value="40.6" lower_limit="25.7" upper_limit="64.0"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (post-vaccination; N=49,48,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107" lower_limit="726" upper_limit="1689"/>
                    <measurement group_id="O2" value="2089" lower_limit="1405" upper_limit="3105"/>
                    <measurement group_id="O3" value="189" lower_limit="140" upper_limit="255"/>
                    <measurement group_id="O4" value="98.2" lower_limit="73.2" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (pre-vaccination; N=49,48,83,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.1" upper_limit="35.1"/>
                    <measurement group_id="O2" value="20.0" lower_limit="13.8" upper_limit="28.9"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (post-vaccination; N=49,48,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604" lower_limit="387" upper_limit="944"/>
                    <measurement group_id="O2" value="829" lower_limit="575" upper_limit="1195"/>
                    <measurement group_id="O3" value="25.3" lower_limit="19.1" upper_limit="33.5"/>
                    <measurement group_id="O4" value="17.0" lower_limit="13.6" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Persistence of Seroprotection to JE-CV Antigens Up To Five Years Following Vaccination</title>
        <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
        <time_frame>Day 0 (pre-vaccination) up to 5 years after final vaccination</time_frame>
        <population>Persistence of seroprotection to JE-CV antigens was assessed in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Persistence of Seroprotection to JE-CV Antigens Up To Five Years Following Vaccination</title>
          <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
          <population>Persistence of seroprotection to JE-CV antigens was assessed in the Full Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homologous virus (pre-vaccination; N=50,50,100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="15" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-vaccination; N=49,50,98,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="98" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="89" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-6 months; N=48,49,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="91" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="80" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-1 year; N=48,45,91,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="81" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="71" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-2 years; N=43,41,85,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="74" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="64" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-3 years; N=40,38,68,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="66" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="52" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-4 years; N=41,36,63,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="36" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="63" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="54" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-5 years; N=40,38,60,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="55" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="44" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (pre-vaccination; N=50,50,97,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="95" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="93" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (post-6 months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="95" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="86" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (pre-vaccination; N=49,50,97,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="93" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="93" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (post-6 months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="90" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="80" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (pre-vaccination; N=50,50,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="92" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (post-6 months; N=48,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="73" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="62" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (pre-vaccination; N=49,50,97,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="73" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="65" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (post-6 months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="68" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="46" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Geometric Mean Titer Against JE Antibodies Up To Five Years Following Vaccination With JE-CV Vaccine</title>
        <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
        <time_frame>Day 0 (pre-vaccination) up to 5 years after final vaccination</time_frame>
        <population>Geometric Mean Titers Against JE Antibodies were assessed in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV/Hepatitis A (Group 1)</title>
            <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE-CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O2">
            <title>Hepatitis A/JE-CV (Group 2)</title>
            <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/Hepatitis A (Group 3)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of JE-CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
          </group>
          <group group_id="O4">
            <title>Hepatitis A/JE-CV (Group 4)</title>
            <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE-CV as second vaccination 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titer Against JE Antibodies Up To Five Years Following Vaccination With JE-CV Vaccine</title>
          <description>Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay.</description>
          <population>Geometric Mean Titers Against JE Antibodies were assessed in the Full Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homologous virus (pre-vaccination; N=50,50,100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" lower_limit="33.5" upper_limit="70.4"/>
                    <measurement group_id="O2" value="41.1" lower_limit="27.2" upper_limit="62.2"/>
                    <measurement group_id="O3" value="6.11" lower_limit="5.51" upper_limit="6.78"/>
                    <measurement group_id="O4" value="5.15" lower_limit="4.94" upper_limit="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-vaccination; N=49,50,98,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1956.7" lower_limit="1227.1" upper_limit="3120.0"/>
                    <measurement group_id="O2" value="3722.2" lower_limit="2489.2" upper_limit="5565.9"/>
                    <measurement group_id="O3" value="517.6" lower_limit="371.7" upper_limit="720.9"/>
                    <measurement group_id="O4" value="167.1" lower_limit="120.2" upper_limit="232.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-6 months; N=48,49,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="892.1" lower_limit="566.1" upper_limit="1405.8"/>
                    <measurement group_id="O2" value="1244.3" lower_limit="798.8" upper_limit="1938.3"/>
                    <measurement group_id="O3" value="96.6" lower_limit="71.4" upper_limit="130.9"/>
                    <measurement group_id="O4" value="49.8" lower_limit="36.8" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-1 year; N=48,45,91,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339" lower_limit="216" upper_limit="531"/>
                    <measurement group_id="O2" value="621" lower_limit="382" upper_limit="1009"/>
                    <measurement group_id="O3" value="78.8" lower_limit="57.8" upper_limit="107"/>
                    <measurement group_id="O4" value="49.0" lower_limit="34.9" upper_limit="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-2 years; N=43,41,85,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414" lower_limit="246" upper_limit="698"/>
                    <measurement group_id="O2" value="662" lower_limit="403" upper_limit="1088"/>
                    <measurement group_id="O3" value="94.2" lower_limit="66.0" upper_limit="134"/>
                    <measurement group_id="O4" value="67.1" lower_limit="46.3" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-3 years; N=40,38,68,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422" lower_limit="273" upper_limit="654"/>
                    <measurement group_id="O2" value="505" lower_limit="339" upper_limit="751"/>
                    <measurement group_id="O3" value="146" lower_limit="102" upper_limit="208"/>
                    <measurement group_id="O4" value="90.5" lower_limit="62.6" upper_limit="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-4 years; N=41,36,63,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="223" upper_limit="582"/>
                    <measurement group_id="O2" value="559" lower_limit="306" upper_limit="1023"/>
                    <measurement group_id="O3" value="137" lower_limit="100" upper_limit="188"/>
                    <measurement group_id="O4" value="110" lower_limit="77.5" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous virus (post-5 years; N=40,38,60,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" lower_limit="151" upper_limit="328"/>
                    <measurement group_id="O2" value="287" lower_limit="183" upper_limit="449"/>
                    <measurement group_id="O3" value="68.8" lower_limit="48.3" upper_limit="98.1"/>
                    <measurement group_id="O4" value="58.2" lower_limit="36.4" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (pre-vaccination; N=50,50,97,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="36.1" upper_limit="83.3"/>
                    <measurement group_id="O2" value="55.3" lower_limit="35.2" upper_limit="86.9"/>
                    <measurement group_id="O3" value="5.62" lower_limit="5.18" upper_limit="6.11"/>
                    <measurement group_id="O4" value="5.18" lower_limit="4.96" upper_limit="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1015.8" lower_limit="703.4" upper_limit="1466.9"/>
                    <measurement group_id="O2" value="2116.7" lower_limit="1519.8" upper_limit="2948.1"/>
                    <measurement group_id="O3" value="186.8" lower_limit="142.2" upper_limit="245.3"/>
                    <measurement group_id="O4" value="163.1" lower_limit="122.5" upper_limit="217.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype I (6-months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="863.5" lower_limit="573.9" upper_limit="1299.3"/>
                    <measurement group_id="O2" value="981.0" lower_limit="678.4" upper_limit="1418.4"/>
                    <measurement group_id="O3" value="81.4" lower_limit="62.8" upper_limit="105.5"/>
                    <measurement group_id="O4" value="52.4" lower_limit="40.2" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (pre-vaccination; N=49,50,97,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="31.9" upper_limit="67.9"/>
                    <measurement group_id="O2" value="33.3" lower_limit="22.3" upper_limit="49.6"/>
                    <measurement group_id="O3" value="5.75" lower_limit="5.16" upper_limit="6.40"/>
                    <measurement group_id="O4" value="5.20" lower_limit="4.90" upper_limit="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="920.6" lower_limit="624.9" upper_limit="1356.2"/>
                    <measurement group_id="O2" value="1763.4" lower_limit="1199.3" upper_limit="2592.9"/>
                    <measurement group_id="O3" value="163.2" lower_limit="125.5" upper_limit="212.3"/>
                    <measurement group_id="O4" value="126.8" lower_limit="97.8" upper_limit="164.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype II (post-6 months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.2" lower_limit="402.9" upper_limit="838.3"/>
                    <measurement group_id="O2" value="714.4" lower_limit="520.4" upper_limit="980.7"/>
                    <measurement group_id="O3" value="72.3" lower_limit="54.4" upper_limit="96.1"/>
                    <measurement group_id="O4" value="42.4" lower_limit="31.7" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (pre-vaccination; N=50,50,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="25.8" upper_limit="54.7"/>
                    <measurement group_id="O2" value="41.1" lower_limit="26.5" upper_limit="63.7"/>
                    <measurement group_id="O3" value="5.39" lower_limit="5.04" upper_limit="5.76"/>
                    <measurement group_id="O4" value="5.08" lower_limit="4.93" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107.1" lower_limit="725.8" upper_limit="1688.7"/>
                    <measurement group_id="O2" value="2210.4" lower_limit="1498.2" upper_limit="3261.0"/>
                    <measurement group_id="O3" value="200.2" lower_limit="151.5" upper_limit="264.6"/>
                    <measurement group_id="O4" value="102.1" lower_limit="75.8" upper_limit="137.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype III (post-6 months; N=48,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.1" lower_limit="326.5" upper_limit="806.5"/>
                    <measurement group_id="O2" value="645.7" lower_limit="438.7" upper_limit="950.4"/>
                    <measurement group_id="O3" value="31.1" lower_limit="23.3" upper_limit="41.5"/>
                    <measurement group_id="O4" value="20.2" lower_limit="15.6" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (pre-vaccination; N=49,50,97,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.1" upper_limit="35.1"/>
                    <measurement group_id="O2" value="19.7" lower_limit="13.8" upper_limit="28.2"/>
                    <measurement group_id="O3" value="5.31" lower_limit="5.03" upper_limit="5.60"/>
                    <measurement group_id="O4" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (post-vaccination; N=49,50,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604.0" lower_limit="386.6" upper_limit="943.6"/>
                    <measurement group_id="O2" value="874.0" lower_limit="610.0" upper_limit="1252.3"/>
                    <measurement group_id="O3" value="28.5" lower_limit="21.5" upper_limit="37.7"/>
                    <measurement group_id="O4" value="18.1" lower_limit="14.3" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype IV (post-6 months; N=47,48,99,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279.4" lower_limit="194.1" upper_limit="402.3"/>
                    <measurement group_id="O2" value="363.4" lower_limit="256.8" upper_limit="514.3"/>
                    <measurement group_id="O3" value="21.0" lower_limit="16.2" upper_limit="27.2"/>
                    <measurement group_id="O4" value="12.6" lower_limit="9.93" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to Day 28 post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>JE CV/Hepatitis A (Group 1)</title>
          <description>Children aged 2 to 5 years of age received one dose of Japanese Encephalitis ChimeriVax™ (JE CV) as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="E2">
          <title>Hepatitis A/JE CV (Group 2)</title>
          <description>Children aged 2 to 5 years of age received one dose of Hepatitis A as first vaccination and one dose of JE CV as second vaccination 28 days apart</description>
        </group>
        <group group_id="E3">
          <title>JE CV/Hepatitis A (Group 3)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of JE CV as first vaccination and one dose of Hepatitis A as second vaccination 28 days apart</description>
        </group>
        <group group_id="E4">
          <title>Hepatitis A/JE CV (Group 4)</title>
          <description>Toddlers aged 12 to 24 months of age received one dose of Hepatitis A as first vaccination and one dose of JE CV as second vaccination 28 days apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection-site tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="43" subjects_affected="43" subjects_at_risk="101"/>
                <counts group_id="E4" events="20" subjects_affected="20" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E4" events="28" subjects_affected="28" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" events="35" subjects_affected="35" subjects_at_risk="101"/>
                <counts group_id="E4" events="39" subjects_affected="35" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite lost</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="101"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="101"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="101"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="101"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heat rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

